Collisions between particles at high energies can sometimes produce new particles and shed light on interactions between the ...
Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results